{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:57:36Z","timestamp":1772791056787,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ejso.2016.05.039","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T16:15:33Z","timestamp":1466698533000},"page":"1146-1152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study"],"prefix":"10.1016","volume":"42","author":[{"given":"Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-w.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-d.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.-z.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.-m.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2016.05.039_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000335347","article-title":"Neoadjuvant therapy \u2013 what have we achieved in the last 20 years?","volume":"6","author":"Huober","year":"2011","journal-title":"Breast Care"},{"key":"10.1016\/j.ejso.2016.05.039_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejso.2013.05.002","article-title":"Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy","volume":"39","author":"Navarro-Cecilia","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2016.05.039_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00595-010-4404-z","article-title":"Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer","volume":"41","author":"Shimazu","year":"2011","journal-title":"Surg Today"},{"key":"10.1016\/j.ejso.2016.05.039_bib4","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.05.039_bib5","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","article-title":"Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy","volume":"11","author":"Gianni","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2016.05.039_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2016.05.039_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18","volume":"30","author":"Wolmark","year":"2001","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejso.2016.05.039_bib8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"13","author":"Bear","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.05.039_bib9","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.05.039_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.5858\/2000-124-0966-PFIBC","article-title":"Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999","volume":"7","author":"Fitzgibbons","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejso.2016.05.039_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1634\/theoncologist.2012-0057","article-title":"Weekly paclitaxel\/Carboplatin\/Trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule","volume":"18","author":"Yu","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2016.05.039_bib12","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejso.2016.05.039_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","article-title":"Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer","volume":"11","author":"Baselga","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2016.05.039_bib14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejso.2016.05.039_bib15","volume":"32","author":"Piccart-Gebhart","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.05.039_bib16","doi-asserted-by":"crossref","first-page":"e114646","DOI":"10.1371\/journal.pone.0114646","article-title":"ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2016.05.039_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.21911","article-title":"The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer\u2013a systematic review and meta-analysis","volume":"104","author":"Tan","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.05.039_bib18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316305881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316305881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:48:26Z","timestamp":1656730106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798316305881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0748798316305881"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.05.039","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd, BASO ~ the Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}